Literature DB >> 2536470

Receptor binding of [3H]naloxone benzoylhydrazone: a reversible kappa and slowly dissociable mu opiate.

M Price1, M A Gistrak, Y Itzhak, E F Hahn, G W Pasternak.   

Abstract

In standard 3H-opioid binding assays, the benzoylhydrazone derivative of naloxone (6-desoxy-6-benzoylhydrazido-N-allyl-14-hydroxydihydronormorphi none; NalBzoH) inhibited mu, kappa, and delta binding at nanomolar concentrations. At concentrations as low as 1 nM, it also produced a wash-resistant inhibition of opioid binding. [3H]NalBzoH binding typically gave a ratio of total to nonspecific binding of 8:1. Binding reached steady state levels by 1 hr and was linear with tissue concentration. [3H]NalBzoH labeled two classes of sites. The binding to one was easily reversible whereas the other was not and was termed pseudoirreversible. At 25 degrees, almost 90% of [3H]naloxone binding and approximately 60-75% of [3H]NalBzoH binding dissociated over 90 min. However, the remainder of [3H]NalBzoH binding, corresponding to pseudoirreversible binding, remained constant over the next 5 hr at 25 degrees and additional studies suggested a dissociation half-life of approximately 24 hr. Competition studies indicated that the reversible binding corresponded to neither mu nor delta binding and may represent a novel subtype of kappa receptor. Pseudoirreversible binding was predominantly to a combination of both mu 1 and mu 2 receptors. Despite its extremely slow rate of dissociation, pseudoirreversible binding was not covalent inasmuch as lowering the pH to 5 or adding the GTP analog 5'-guanylylimidodiphosphate [Gpp(NH)p] completely dissociated prebound [3H] NalBzoH. The ability of Gpp(NH)p to dissociate pseudoirreversible [3H]NalBzoH binding raised the possibility that the slow rate of dissociation was related to interactions with a guanine nucleotide-binding protein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536470

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Has the sun set on kappa3-opioid receptors?

Authors:  Mark Connor; Ian Kitchen
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

2.  Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.

Authors:  Susruta Majumdar; Steven Grinnell; Valerie Le Rouzic; Maxim Burgman; Lisa Polikar; Michael Ansonoff; John Pintar; Ying-Xian Pan; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

3.  Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.

Authors:  Maria C Olianas; Danilo Concas; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

4.  Affinity labeling mu opioid receptors with novel radioligands.

Authors:  Ke Yang; Amy Zuckerman; Gavril W Pasternak
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

5.  G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.

Authors:  Pierluigi Onali; Maria C Olianas
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

6.  Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase.

Authors:  Qingshan Wang; Hui Zhou; Huiming Gao; Shih-Heng Chen; Chun-Hsien Chu; Belinda Wilson; Jau-Shyong Hong
Journal:  J Neuroinflammation       Date:  2012-02-16       Impact factor: 8.322

Review 7.  Review of Kyotorphin Research: A Mysterious Opioid Analgesic Dipeptide and Its Molecular, Physiological, and Pharmacological Characteristics.

Authors:  Hiroshi Ueda
Journal:  Front Med Technol       Date:  2021-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.